On-Demand CME Videos
FC24: Chronic Hand Eczema: Hope on the Horizon: An Online Activity
About
FC24: Chronic Hand Eczema: Hope on the Horizon: An Online Activity
This activity is supported by an educational grant from LEO Pharma.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
December 12, 2024
December 12, 2025
Learning Objectives
At the completion of this activity, participants should be better able to:
Describe the diverse clinical presentation of chronic hand eczema
Define the role of new and emerging topical therapies for the management of chronic hand eczema
Identify treatment plans for patients who would benefit from new and emerging topical therapies based on patient characteristics, preferences, and treatment goals
Intended Audience
Faculty
April Armstrong, MD, MPH
Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA
Linda Stein Gold, MD
Director Clinical Research
Henry Ford Health System
Detroit, MI
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Advisory Board/Consultant: AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Takeda, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Regeneron, Pfizer
Grant/Research Support: AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Takeda, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Regeneron, and Pfizer
Grant/Research Support: Arcutis, BMS, Incyte, Dermavant, Galderma, Lilly, AbbVie
Consultant: Arcutis, BMS, Incyte, Dermavant, Galderma, Lilly, AbbVie
Speakers’ Bureau or Honoraria: Leo, AbbVie, Almirall, Galderma, Pfizer, Sanofi, Regeneron
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.